Development of BMS-986453, a Dual-Targeting BCMAxGPRC5D Chimeric Antigen Receptor (CAR) for the Treatment of Multiple Myeloma (IMS 2026) - Sep 11, 2026 - Abstract #PA-145; Pres time: Sep 24, 2026; P1 | "The objective was to design, optimize, and evaluate dual-targeting BCMA×GPRC5D CAR T cell therapy for MM. High BCMA and GPRC5D expression in patients with ≥3 prior LOT confirms their suitability as dual-targeting CAR antigens. The loop tandem design was superior to bicistronic or linear tandem approaches, and the resulting CAR demonstrated potent dual-antigen activity in preclinical studies. These data supported advancement of BMS-986453 into clinical development, where early phase 1 results (NCT06153251) indicate a highly functional and potent CAR capable of effectively targeting BCMA and GPRC5D in patients."
First-in-human • IO biomarker • Hematological Malignancies • Multiple Myeloma • GPRC5D
|
|
Kimberly Harrington1; Jon C. Jones1; Yeonjoo Oh2; Heather Striegel1; Eric Jeffery1; Cyr De Imus1; Kristen Dang1; Timothy Johnstone1; Andrew Drake1; Fatima Javier1; Nels Hamacher1; Asanga Weliwitigoda1; Dhong Hyun Lee1; Mike Liu1; Jamie Jackson1; Shari Kaiser1; Luciano J. Costa3; Sham Mailankody4; Surbhi Sidana5; Adriana Rossi6; Doris Hansen7; Colin Godwin1; Ruth Salmon1; Douglas Jones1
|